Ribociclib (RIB) plus letrozole (LET) in subgroups of special clinical interest with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Subgroup analysis from the CompLEEment-1 trial

Cottu, P. H.Ring, A.Marchetti, P.Cardoso, F.Salvador, J.Neven, P.Papazisis, K.Campone, M.Bachelot, T.Menon-Singh, L.Wu, J.Zhou, K.De laurentiis, M.2025-01-072025-01-072020-09-010923-7534https://hdl.handle.net/10668/27218enRibociclib (RIB) plus letrozole (LET) in subgroups of special clinical interest with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Subgroup analysis from the CompLEEment-1 trialconference outputopen access10.1016/j.annonc.2020.08.4351569-8041http://www.annalsofoncology.org/article/S0923753420404314/pdf573469100333